Velphoro 500mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Velphoro 500mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Velphoro 500mg

Property Description
Active ingredient Sucroferric Oxyhydroxide
Form Chewable Tablet; Powder for Oral Suspension
Pharmacological class Phosphate Binder
Common use Management of phosphate levels
Origin Synthetic, Iron-based compound

Velphoro 500mg: Defining its Pharmacological Identity

Velphoro is a specialized, prescription-only medication categorized as a Phosphate Binder, utilized for the management of high phosphate levels. The product's core component is Sucroferric Oxyhydroxide, an active ingredient that has been recognized for its high phosphate-binding efficacy. Unlike older generations of phosphate binders that rely on calcium, Velphoro is an iron-based compound, which serves as a differentiating factor. The 500mg marking denotes the elemental iron equivalent within the total mass of the active compound supplied, confirming its precise formulation.

Composition and Pharmaceutical Form

The core entity, Sucroferric Oxyhydroxide, consists of a polynuclear iron(III)-oxyhydroxide (pn-FeOOH) core stabilized by carbohydrate moieties, including sucrose and starches, ensuring its stability and targeted function within the digestive system. Velphoro is provided for oral use as both a Chewable Tablet and a Powder for Oral Suspension in sachets. This dual availability and the high binding capacity of the compound are distinguishing features that allow for a lower daily tablet count compared to certain other binders.

Core Purpose: Localized Mineral Management

The general purpose of Velphoro is to chemically manage the amount of dietary phosphate absorbed by the body, as its mechanism is strictly confined to the gastrointestinal tract. The medication utilizes the iron-oxyhydroxide core to chemically capture and bind to phosphate ions present in food and fluids. This localized action transforms the soluble phosphate into an insoluble complex, thereby preventing its passage through the intestinal wall into the bloodstream. The resulting unabsorbed, bound phosphate is then naturally eliminated from the body, providing foundational support for overall blood mineral balance.

Regulatory References

  1. National Library of Medicine Drug Summary
Advertisements

What side effects are possible with Velphoro 500mg?

Possible Side Effects and Safety Information

Velphoro (sucroferric oxyhydroxide) is generally associated with localized gastrointestinal (GI) side effects, given its minimal systemic absorption. Safety data is primarily derived from governmental regulatory bodies, including the U.S. FDA and the European Medicines Agency (EMA).

Most Common Adverse Reactions

Clinical trials documented the majority of side effects within the Gastrointestinal disorders system-organ class. These were frequently reported as:

  • Very Common (Affecting ge1 in 10 people): Diarrhea and Discolored feces (black stool).
  • Common (Affecting ge1 in 100 people): Nausea, Vomiting, Dyspepsia, Abdominal pain, Flatulence, and Constipation.

The discoloration of stool to black is an expected outcome due to the iron content of the product and should not cause alarm. Diarrhea events are often mild, transient, and may resolve with continued treatment.

Safety Restrictions and Contraindications

Velphoro is formally contraindicated in patients with a known hypersensitivity to the active substance or excipients, and in patients with haemochromatosis or any other disorders involving iron accumulation. Caution and monitoring are advised for patients with certain pre-existing GI or hepatic disorders, or those who have had recent major GI surgery, as these populations were not extensively studied in clinical trials.

Serious or Significant Safety Notes

The black discoloration of stool caused by the medication may visually mask potential gastrointestinal bleeding. Additionally, the drug contains sucrose and starches; therefore, patients with rare hereditary problems such as fructose intolerance or glucose-galactose malabsorption should not take this medicine.

Efficacy and safety have not been established in the pediatric population below the age of two years.

Advertisements

Overdose and Emergency Response

Documented Overdose Status

Official regulatory information for Velphoro (Sucroferric Oxyhydroxide) indicates that no reports of overdosage in patients have been documented in the prescribing information. This profile is defined by statements regarding potential consequences of excessive use rather than a specific systemic overdose syndrome, which is not reported.

Potential Manifestations and Systemic Risk

While clinical cases of overdosage are not reported, the most significant potential consequence is the development of severe hypophosphatemia, an imbalance characterized by excessively low phosphate levels. The regulatory labeling explicitly states that the risk of systemic iron toxicity is low. This low systemic risk is established based on the minimal absorption of the iron-based compound from the gastrointestinal tract, as documented in pharmacological studies.

Regulatory Guidance on Seeking Help

Immediate medical attention is required in the event of an overdose that leads to an adverse metabolic imbalance, such as hypophosphatemia. Official guidance directs that this condition must be managed by healthcare professionals using standard clinical practice. Regulatory documents do not specify a unique antidote or distinct monitoring requirements in the event of overdosage; the approach is focused solely on the supportive management of the resulting metabolic condition.

Advertisements

Therapeutic Uses of Velphoro 500mg

What Velphoro 500mg Treats: Main Uses and Benefits

Velphoro is commonly used in clinical settings to help manage hyperphosphatemia, a condition marked by elevated phosphate levels in the blood that is frequently associated with severe Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD), and is commonly used in the context of advanced kidney failure care. Its primary therapeutic benefit is to support the control of serum phosphorus levels, which is considered relevant for assisting with the management of blood mineral balance. The medication is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort, including CKD-MBD and End-Stage Renal Disease.

Effective management in this domain may assist with mitigating the threat of serious long-term complications, such as vascular calcification and severe skeletal damage. This therapeutic support may assist with the easing of certain symptoms related to systemic imbalance. It may assist with managing uncomfortable manifestations, such as uremic pruritus (symptoms related to physical discomfort).

“Maintaining mineral balance contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.”


Quick Fact: Relief for Systemic Discomfort

The treatment supports the easing of symptoms related to systemic imbalance, such as chronic itching and muscle discomfort, which may assist with maintaining day-to-day comfort.

Regulatory References

  1. NIH DailyMed drug label
Advertisements

Eligibility and Restrictions for Use

Eligibility for Velphoro 500mg: Official Regulatory Guidance

Eligibility for Velphoro 500mg (sucroferric oxyhydroxide) is strictly defined by regulatory bodies like the FDA and EMA. The medication is approved for use in adults (18 years and older) with Chronic Kidney Disease (CKD) to control serum phosphorus levels, including those both on and not on dialysis.


Absolute Prohibitions (Contraindications)

Classification Population/Condition
Contraindicated Patients with hemochromatosis (iron overload disorder).
Contraindicated Patients with known hypersensitivity to sucroferric oxyhydroxide or its excipients.

Restrictions and Limitations

  • Pediatric Patients: Use in patients under 18 years of age is officially not recommended as safety and efficacy have not been established.
  • Gastrointestinal Health: Use is not recommended in patients with severe active gastrointestinal disorders, such as severe active gastritis, esophagitis, or peptic ulcers.
  • Reproductive Status: Use during pregnancy is only recommended if clearly necessary; for breastfeeding mothers, a decision to discontinue the drug or nursing is required due to unknown excretion status.
  • Older Adults (65+): No dose adjustment is required based on age alone.
Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Velphoro (sucroferric oxyhydroxide) has a localized mechanism of action within the gastrointestinal tract, where it binds to phosphate. Because the drug is minimally absorbed systemically, the primary type of interaction is the physicochemical binding of co-administered oral medications, which can lead to reduced systemic drug exposure (decreased AUC/Cmax).

Clinically Relevant Drug Separation Requirements

To mitigate the risk of reduced efficacy, the regulatory labeling specifies mandatory timing separation for certain susceptible oral drugs:

Concomitant Medicine Required Administration Timing
Levothyroxine At least 4 hours before Velphoro
Doxycycline At least 1 hour before Velphoro
Cephalexin At least 1 hour before Velphoro
Acetylsalicylic Acid (Aspirin) At least 1 hour before Velphoro

For other oral medications where reduced bioavailability is clinically significant, separation of administration should be considered. Conversely, co-administration with many common drugs, including warfarin, metoprolol, and digoxin, was found in studies to result in no clinically significant change in their exposure and does not require separation.

Other Interaction Notes

The label notes that Velphoro does not affect the iPTH-lowering effect of active Vitamin D analogues. Patients with a history of hemochromatosis or other iron accumulation disorders require careful monitoring of iron homeostasis due to the iron content of Velphoro.

Advertisements

Mechanism of Action

Targeted Non-Systemic Phosphate Sequestration

Velphoro (sucroferric oxyhydroxide) works by a local, non-systemic mechanism within the gastrointestinal tract. Its active core, a polynuclear iron(III)-oxyhydroxide, acts as a specific, non-absorbable ligand that binds to dietary phosphate ions. This action initiates a mechanistic cascade that forms a stable, insoluble complex, thereby removing phosphate from the GI contents.


Modulation of Enteral Phosphate Absorption

The binding action modifies the availability of phosphate within the enteral pathway, inhibiting the absorption across the intestinal wall. By sequestering the phosphate, the drug limits its bioavailability and dampens the rate of phosphorus transfer into the systemic circulation. This mechanistic modulation results in a decreased net systemic delivery of phosphate, reflected as a reduction in serum phosphate concentration.


Influencing Phosphate-Dependent Regulatory Pathways

The iron core's high affinity for phosphate facilitates the efficient sequestration of dietary phosphate within the GI contents. This control over the phosphate influx alters the systemic phosphate concentration, influencing key regulatory pathways responsive to phosphate levels. By modulating the rate of phosphate entry, the mechanism influences the systemic concentration, thereby altering the activity across phosphate-dependent regulatory pathways.

Advertisements

Dosage and Administration Information

How to Use Velphoro 500mg

Velphoro (sucroferric oxyhydroxide) is strictly for oral administration and is used as part of a long-term plan to manage phosphate levels. Its use is intrinsically linked to mealtimes, as the medication is a phosphate binder that must be present in the gastrointestinal tract when food is consumed. The administration principles are defined by specific instructions to ensure the active ingredient is properly dispersed and timed with dietary intake.


Standard Dosing and Administration

The treatment typically begins with a starting dose of 1,500 mg of elemental iron per day, which corresponds to one 500 mg chewable tablet taken with each of the three main meals daily. This dose is not static; it is part of a titration schedule where adjustments are made in increments or decrements of 500 mg (one tablet) per day, generally as often as every two to four weeks, until the desired serum phosphorus level is achieved. The maximum studied daily dose is 3,000 mg.


Essential Procedural Requirements

Procedural Requirement Instruction Detail
Timing Must be taken with meals; the total daily dose is split across meals.
Administration Manner The chewable tablet must be chewed or crushed completely; do not swallow whole.
Missed Dose If a dose is missed, do not take an extra dose to compensate; resume the schedule with the next meal.

For older adults (ge 65 years) and adolescents (ge 12 years), the starting dose and titration principles are the same as for the general adult population. For pediatric patients (2 to <12 years), the dosing schedule is modified and often utilizes the powder formulation.

Advertisements

Recent Clinical Evidence

Velphoro 500mg: Recent Clinical Evidence


Evidence for Use in Adults with Advanced Kidney Disease on Dialysis

Research has explored the use of this compound primarily through pivotal Randomized Controlled Trials (RCTs). These studies were evaluated in adult patients with Chronic Kidney Disease (CKD) who were undergoing maintenance dialysis (either hemodialysis or peritoneal dialysis). The research examined whether the compound was associated with changes in the levels of the key mineral serum phosphorus and if those levels were tracked within specific target ranges. Active-controlled trials were conducted where the compound was evaluated in trials that included another established agent. Studies tracked the change in serum phosphorus levels and data show patterns related to the overall daily pill burden observed during the study period.

Long-term outcomes regarding serious skeletal or cardiovascular health issues were not evaluated by the controlled trials, as the primary efficacy periods were shorter. Existing studies provide limited insight into how the medicine was observed in patients with severe gastrointestinal conditions or those with a history of iron accumulation disorders, as these groups were generally excluded from pivotal trials.


Evidence for Use in Pediatric Patients (Ages 2 and Up)

The research base includes Phase 3, open-label, active-controlled studies conducted in the pediatric population. These studies was evaluated in children and adolescents ranging from 2 to 17 years of age with advanced CKD. The study design focused on monitoring whether age-dependent target serum phosphorus levels were maintained during the study periods. Research provides insight into short-term changes, but evidence is limited for long-term use. Data for certain groups remain insufficient, most notably for children younger than 2 years of age, where research is ongoing and the profile is not fully established.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Velphoro 500mg (FAQ)


Q: Can I crush or split the Velphoro tablets if I cannot chew them?

Official instructions state that the Velphoro chewable tablet must be completely chewed or crushed before swallowing. Crushing the tablet is a stated alternative to chewing, and this procedure helps ensure the medicine works as intended, as it should not be swallowed whole.


Q: How quickly does Velphoro start working after taking it?

The medicine is designed to work as soon as it is consumed, as its effect is local and non-systemic, meaning it stays in the gut. According to official product information, its mechanism involves binding to phosphate in food contents within the gastrointestinal tract, preventing that phosphate from being absorbed into the body.


Q: How long do patients usually need to take Velphoro?

Velphoro is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD). The medicine is part of a long-term approach to the management of this condition.


Q: Is Velphoro safe for long-term use?

The medicine is part of a long-term treatment plan for managing chronic kidney disease. Clinical safety and efficacy have been evaluated in studies lasting up to 55 weeks. The compound is intended for use over long periods as part of chronic disease management.


Q: Can children or teenagers use Velphoro?

Regulatory bodies have different indications regarding age. The FDA indicates use for pediatric patients 9 years of age and older, while the EMA indicates use for those 2 years of age and older with certain stages of CKD or on dialysis. These indications are detailed in the official guidance documents.


Q: What happens to the iron in Velphoro after it binds phosphate?

The active iron component binds phosphate and forms a stable, insoluble complex. This complex, containing the iron, is then eliminated via the feces. Regulatory documents describe the systemic absorption of the iron from the compound into the bloodstream as very low.


Q: Does taking Velphoro affect how other medicines are absorbed?

Due to its localized mechanism in the stomach and intestines, Velphoro has the potential to physically bind to certain co-administered oral medications. This can lead to a reduced systemic absorption of the other medicine. To mitigate this risk, timing separation for certain susceptible oral drugs is specified by regulatory labeling.


Q: What if I accidentally swallow the whole Velphoro tablet without chewing it?

The official instructions emphasize that the tablet must be chewed or crushed completely. Swallowing the tablet whole is described as potentially resulting in reduced effectiveness in binding phosphate, as the active ingredient may not be properly exposed to the food contents.


Q: Can Velphoro affect my iron levels?

The medicine is an iron-based compound. However, regulatory information indicates that the iron component is only minimally absorbed into the bloodstream. The risk of systemic iron toxicity from the drug itself is considered negligible in cases of overdose.


Q: Is Velphoro the same as other phosphate binders?

Velphoro is categorized as a phosphate binder. It is defined as an iron-based phosphate binder, which is distinct from older generations of binders that used other components, such as calcium.


Q: Why do people say Velphoro is easier to take than other treatments?

Clinical studies have examined the compound’s high phosphate-binding efficacy. Evidence indicates that this efficacy allows for a reduced average daily pill burden compared to some other phosphate binders.


Q: Does Velphoro interact with common over-the-counter pain relievers?

Official labeling requires a timing separation when taken with acetylsalicylic acid (Aspirin), which is available over-the-counter. For other oral medications, if a reduction in absorption is considered clinically significant, separation of administration may be considered.


Q: Are there any foods or drinks I should avoid when using Velphoro?

Regulatory information indicates that Velphoro must be taken with meals or snacks to function correctly. The official documentation does not list any specific foods or drinks that should be strictly avoided with the medication itself.


Q: Does Velphoro come in different strengths or forms?

Velphoro is supplied as a 500 mg chewable tablet. It is also available in a different pharmaceutical form as a powder for oral suspension, as described in regulatory documents.


Q: Is Velphoro safe to use during pregnancy or while breastfeeding?

For pregnancy, use is only recommended if a medical professional determines that the expected benefit justifies the potential risk. For breastfeeding, it is not known if the medicine passes into human milk, and a decision must be made by a physician regarding use.


Q: Is Velphoro suitable for people who have had kidney transplants?

The medication is indicated for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD). While the official documentation does not specifically address use in post-transplant patients, the indication is general to CKD management.


Q: What is the biggest risk of not taking Velphoro as prescribed?

The purpose of the medicine is to control high serum phosphorus levels. The primary risk of not adhering to the prescribed schedule is the failure to maintain control of serum phosphorus levels.


Q: Can Velphoro change the color of my urine?

Official safety documents list discolored feces (black stool) as a very common side effect due to the iron content. However, a change in the color of the urine is not listed among the common known adverse reactions.


Q: Does Velphoro affect blood sugar levels for people with diabetes?

The medicine contains sucrose and starches as inactive ingredients. These carbohydrates can be broken down and absorbed into the blood. Due to this content, the medicine may be considered in the overall management of individuals with diabetes.


Q: Are there any known interactions between Velphoro and thyroid medication?

Yes, regulatory information requires that a common thyroid medicine, levothyroxine, must be taken at least 4 hours before Velphoro. This timing separation is required to ensure that the thyroid medicine is fully absorbed and its efficacy is not reduced.


Q: Can Velphoro cause problems with my teeth or mouth?

Since the medicine is a chewable tablet, tooth discoloration was reported as an adverse event in some patients studied in clinical trials. This is a potential effect noted in the official safety information.


Q: What are the clinical trial results for Velphoro?

Pivotal clinical trials were designed to test the medicine's ability to reduce phosphate. Evidence from these studies indicates that the medicine was associated with a reduction in serum phosphorus levels. A majority of patients studied achieved target serum phosphorus levels when taking daily doses within a common range.


Q: Does taking Velphoro make my stools soft or hard?

Changes in stool consistency are common when taking Velphoro. Official documents list both diarrhea (very common) and constipation (common) as potential side effects. The specific effect on stool consistency can vary among individuals.


Q: Can Velphoro interact with vitamins or mineral supplements?

Since Velphoro is a phosphate binder, it has the potential to bind to other substances. Official guidance includes the recommendation that patients inform their doctor about the use of all medicines, vitamins, and other supplements they take.


Q: Is it possible to take too much Velphoro?

No case of overdose has been reported in clinical trials. Regulatory information states that any instance of excessive intake may need to be managed by treating potential complications such as very low phosphate levels (hypophosphatemia) using standard clinical practice.


Q: Can Velphoro cause problems with sleep?

Problems with sleep or disorders of the nervous system are not listed among the very common or common side effects documented in the official clinical trial safety data for this medicine.


Q: Has Velphoro been approved in other countries besides the US and Europe?

In addition to the United States and European Union, the compound has also received regulatory approval from authorities in several other major markets, including China and Japan.


Q: Does Velphoro affect how my bones feel?

Clinical trials focused on reducing serum phosphorus levels over shorter periods. Regulatory documents note that long-term outcomes regarding serious skeletal health issues were not evaluated in the pivotal controlled trials for the medicine.


Q: Can taking Velphoro make me feel tired?

Fatigue or tiredness is not listed among the very common or common adverse reactions documented in the official clinical trial safety data for Velphoro.


Q: Does Velphoro interact with blood pressure medications?

Studies examining potential interactions found that co-administration with common blood pressure medications, such as metoprolol, resulted in no clinically significant change in their systemic exposure, as noted in the regulatory documents.


Q: Can I take Velphoro if I have a history of certain bowel conditions?

Official information states that use is not recommended in patients with certain severe active gastrointestinal disorders, such as severe active gastritis, esophagitis, or peptic ulcers. The official documents detail specific restrictions related to pre-existing gastrointestinal conditions.

Advertisements

How should Velphoro 500mg be stored and disposed of?

How to Store and Dispose of Velphoro 500mg?

The official storage conditions for Velphoro 500 mg chewable tablets focus on maintaining product stability and ensuring child safety, as documented in regulatory labeling.


Storage Requirements

Condition Requirement
Temperature Store below 30°C (86°F); Do not freeze.
Protection Keep the bottle tightly closed to protect the tablets from moisture.
Container Store in the original container.
Child Safety Keep out of the sight and reach of children.
Stability Must be used within 90 days after opening the bottle.

Disposal

Unused or expired Velphoro must be disposed of in accordance with local requirements. It is often recommended to return the medicine to a pharmacist or designated collection point for safe pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Velphoro 500mg found in:

A-Z Index: